Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis.
chronic active lesions
fingolimod
primary progressive multiple sclerosis
slowly expanding lesions (SELs)
volumetric MRI
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
05
09
2023
received:
31
05
2023
accepted:
21
09
2023
pubmed:
12
10
2023
medline:
12
10
2023
entrez:
12
10
2023
Statut:
ppublish
Résumé
Newly appearing lesions in multiple sclerosis (MS) may evolve into chronically active, slowly expanding lesions (SELs), leading to sustained disability progression. The aim of this study was to evaluate the incidence of newly appearing lesions developing into SELs, and their correlation to clinical evolution and treatment. A retrospective analysis of a fingolimod trial in primary progressive MS (PPMS; INFORMS, NCT00731692) was undertaken. Data were available from 324 patients with magnetic resonance imaging scans up to 3 years after screening. New lesions at year 1 were identified with convolutional neural networks, and SELs obtained through a deformation-based method. Clinical disability was assessed annually by Expanded Disability Status Scale (EDSS), Nine-Hole Peg Test, Timed 25-Foot Walk, and Paced Auditory Serial Addition Test. Linear, logistic, and mixed-effect models were used to assess the relationship between the Jacobian expansion in new lesions and SELs, disability scores, and treatment status. One hundred seventy patients had ≥1 new lesions at year 1 and had a higher lesion count at screening compared to patients with no new lesions (median = 27 vs. 22, p = 0.007). Among the new lesions (median = 2 per patient), 37% evolved into definite or possible SELs. Higher SEL volume and count were associated with EDSS worsening and confirmed disability progression. Treated patients had lower volume and count of definite SELs (β = -0.04, 95% confidence interval [CI] = -0.07 to -0.01, p = 0.015; β = -0.36, 95% CI = -0.67 to -0.06, p = 0.019, respectively). Incident chronic active lesions are common in PPMS, and fingolimod treatment can reduce their number.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Newly appearing lesions in multiple sclerosis (MS) may evolve into chronically active, slowly expanding lesions (SELs), leading to sustained disability progression. The aim of this study was to evaluate the incidence of newly appearing lesions developing into SELs, and their correlation to clinical evolution and treatment.
METHODS
METHODS
A retrospective analysis of a fingolimod trial in primary progressive MS (PPMS; INFORMS, NCT00731692) was undertaken. Data were available from 324 patients with magnetic resonance imaging scans up to 3 years after screening. New lesions at year 1 were identified with convolutional neural networks, and SELs obtained through a deformation-based method. Clinical disability was assessed annually by Expanded Disability Status Scale (EDSS), Nine-Hole Peg Test, Timed 25-Foot Walk, and Paced Auditory Serial Addition Test. Linear, logistic, and mixed-effect models were used to assess the relationship between the Jacobian expansion in new lesions and SELs, disability scores, and treatment status.
RESULTS
RESULTS
One hundred seventy patients had ≥1 new lesions at year 1 and had a higher lesion count at screening compared to patients with no new lesions (median = 27 vs. 22, p = 0.007). Among the new lesions (median = 2 per patient), 37% evolved into definite or possible SELs. Higher SEL volume and count were associated with EDSS worsening and confirmed disability progression. Treated patients had lower volume and count of definite SELs (β = -0.04, 95% confidence interval [CI] = -0.07 to -0.01, p = 0.015; β = -0.36, 95% CI = -0.67 to -0.06, p = 0.019, respectively).
CONCLUSIONS
CONCLUSIONS
Incident chronic active lesions are common in PPMS, and fingolimod treatment can reduce their number.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16092Subventions
Organisme : Multiple Sclerosis Society
Pays : United Kingdom
Informations de copyright
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132-1140. doi:10.1001/JAMANEUROL.2020.1568
Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013;12(7):669-676. doi:10.1016/S1474-4422(13)70103-0
Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler. 1999;5:283-286. doi:10.1177/135245859900500415
Stevenson VL, Miller DH, Rovaris M, et al. Primary and transitional progressive MS. Neurology. 1999;52(4):839. doi:10.1212/WNL.52.4.839
Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710-721. doi:10.1002/ana.24497
Luchetti S, Fransen NL, Van Eden CG, Ramaglia V, Mason M, Huitinga I. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol. 2018;135(4):511-528. doi:10.1007/s00401-018-1818-y
Calvi A, Haider L, Prados F, Tur C, Chard D, Barkhof F. In vivo imaging of chronic active lesions in multiple sclerosis. Mult Scler J. 2020;28(5):135245852095858. SAGE Publications Ltd. doi:10.1177/1352458520958589
Dal-Bianco A, Grabner G, Kronnerwetter C, et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol. 2017;133(1):25-42. doi:10.1007/s00401-016-1636-z
Elliott C, Wolinsky JS, Hauser SL, et al. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler J. 2019;25(14):1915-1925. doi:10.1177/1352458518814117
Elliott C, Arnold DL, Chen H, et al. Patterning chronic active demyelination in slowly expanding/evolving white matter MS lesions. Am J Neuroradiol. 2020;41(9):1584-1591. doi:10.3174/AJNR.A6742
Calvi A, Carrasco FP, Tur C, et al. Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis. Neurology. 2022;98(17):E1783-E1793. doi:10.1212/WNL.0000000000200144
Calvi A, Tur C, Chard D, et al. Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis. NeuroImage Clin. 2022;35:103048. doi:10.1016/j.nicl.2022.103048
Preziosa P, Pagani E, Meani A, et al. Slowly expanding lesions predict 9-year multiple sclerosis disease progression. Neurol Neuroimmunol Neuroinflamm. 2022;9(2):E1139. doi:10.1212/NXI.0000000000001139
Klistorner S, Barnett MH, Yiannikas C, et al. Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter. Mult Scler J. 2022;28(5):697-706. doi:10.1177/13524585211033464
Martínez-Heras E, Solana E, Prados F, et al. Characterization of multiple sclerosis lesions with distinct clinical correlates through quantitative diffusion MRI. NeuroImage lin. 2020;28:102411. doi:10.1016/J.NICL.2020.102411
Calvi A, Clarke MA, Prados F, et al. Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis. Mult scler. 2023;29(3):352-362. doi:10.1177/13524585221141964
Elliott C, Rudko DA, Arnold DL, et al. Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis. Mult Scler J. 2023;29:680-690. doi:10.1177/13524585231162262
Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075-1084. doi:10.1016/S0140-6736(15)01314-8
Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. doi:10.1016/S0140-6736(18)30475-6. www.thelancet.com
Valverde S, Cabezas M, Roura E, et al. Improving automated multiple sclerosis lesion segmentation with a cascaded 3D convolutional neural network approach. Neuroimage. 2017;155:159-168. doi:10.1016/j.neuroimage.2017.04.034
Cardoso MJ, Modat M, Wolz R, et al. Geodesic information flows: spatially-variant graphs and their application to segmentation and fusion. IEEE Trans Med Imaging. 2015;34(9):1976-1988. doi:10.1109/TMI.2015.2418298
Prados F, Cardoso MJ, Kanber B, et al. A multi-time-point modality-agnostic patch-based method for lesion filling in multiple sclerosis. Neuroimage. 2016;139:376-384. doi:10.1016/j.neuroimage.2016.06.053
Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002;17(1):479-489. doi:10.1006/nimg.2002.1040
Lassmann H, Raine CS, Antel J, Prineas JW. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol. 1998;86(2):213-217. doi:10.1016/S0165-5728(98)00031-9
Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol. 2001;50(5):646-657. doi:10.1002/ana.1255
De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010;74(23):1868-1876. doi:10.1212/WNL.0b013e3181e24136
Rahmanzadeh R, Lu PJ, Barakovic M, et al. Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging. Brain. 2021;144(6):1684-1696. doi:10.1093/brain/awab088
Cagol A, Schaedelin S, Barakovic M, et al. ‘Association of Brain Atrophy with Disease Progression Independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol. 2022;79(7):682-692. doi:10.1001/JAMANEUROL.2022.1025
Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, et al. Association of Early Progression Independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurology. 2023;80(2):151-160. doi:10.1001/JAMANEUROL.2022.4655
Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology. 2001;57(4):731-733. doi:10.1212/WNL.57.4.731
Elliott C, Belachew S, Wolinsky JS, et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain. 2019;142(9):2787-2799. doi:10.1093/brain/awz212
Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460-471. doi:10.1002/ANA.21867
García-Lorenzo D, Francis S, Narayanan S, Arnold DL, Collins DL. Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging. Med Image Anal. 2013;17:1-18. doi:10.1016/j.media.2012.09.004